Comparison of Four Cisplatin-Based Radiochemotherapy Regimens for Nonmetastatic Stage III/IV Squamous Cell Carcinoma of the Head and Neck;Head-and-neck cancer; Cisplatin-based radiochemotherapy; Toxicity; Treatment outcomes

Journal Article · Fri Jul 15 04:00:00 EDT 2011 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/j.ijrobp.2010.03.033· OSTI ID:21587631

Rades, Dirk ^[1]; Kronemann, Stefanie; Meyners, Thekla; Bohlen, Guenther ^[1]; Tribius, Silke ^[2]; Kazic, Nadja ^[3]; Schroeder, Ursula ^[4]; Hakim, Samer G ^[5]; Schild, Steven E ^[6]; Dunst, Juergen ^[1]

---

1. Department of Radiation Oncology, University of Lubeck, Lubeck (Germany)
2. Department of Radiation Oncology, University of Hamburg, Hamburg (Germany)
3. Department of Radiation Oncology, University of Sarajevo, Sarajevo (Bosnia and Herzegowina)
4. Department of Head and Neck Surgery, University of Lubeck, Lubeck (Germany)
5. Department of Maxillofacial Surgery, University of Lubeck, Lubeck (Germany)
6. Department of Radiation Oncology, Mayo Clinic, Scottsdale, AR (United States)

Purpose: To compare the outcomes of four cisplatin-based radiochemotherapy regimens in 311 patients with Stage III/IV squamous cell carcinoma of the head and neck. Methods and Materials: Concurrent chemotherapy consisted of three courses of cisplatin 100 mg/m{sup 2} on Day 1 (Group A, n = 74), two courses of cisplatin 20 mg/m{sup 2} on Days 1-5 plus 5-fluorouracil 1,000 mg/m{sup 2} on Days 1-5 (Group B, n = 49), two courses of cisplatin 20 mg/m{sup 2} on Days 1-5 plus 5-fluorouracil 600 mg/m{sup 2} on Days 1-5 (Group C, n = 102), or two courses of cisplatin 20 mg/m{sup 2} on Days 1-5 (Group D, n = 86). The groups were retrospectively compared for toxicity and outcomes, and 11 additional factors were evaluated for outcomes. Results: No significant difference was observed among the groups regarding radiation-related acute oral mucositis and radiation-related late toxicities. Acute Grade 3 skin toxicity was significantly more frequent in Group B than in the patients of the other three groups (p = .013). The chemotherapy-related Grade 3 nausea/vomiting rate was 24% for Group A, 8% for Group B, 9% for Group C, and 6% for Group D (p = .003). The corresponding Grade 3 nephrotoxicity rates were 8%, 1%, 2%, and 1% (p = .019). The corresponding Grade 3-4 hematologic toxicity rates were 35%, 41%, 19%, and 21% (p = .027). Chemotherapy could be completed in 50%, 59%, 74%, and 83% of the Group A, B, C, and D patients, respectively (p = .002). Toxicity-related radiotherapy breaks occurred in 39%, 43%, 21%, and 15% of Groups A, B, C, and D, respectively (p = .005). The 3-year locoregional control rate was 67%, 72%, 60%, and 59% for Groups A, B, C, and D, respectively (p = .48). The corresponding 3-year metastasis-free survival rates were 67%, 74%, 63%, and 79% (p = .31), and the corresponding 3-year survival rates were 60%, 63%, 50%, and 71% (p = .056). On multivariate analysis, Karnofsky performance status, histologic grade, T/N category, preradiotherapy hemoglobin level, completion of chemotherapy, and radiotherapy breaks were associated with the outcome. Conclusion: The four compared radiochemotherapy regimens were not significantly different regarding treatment outcomes. Two courses of cisplatin 20 mg/m{sup 2} on Days 1-5 were better tolerated than the other three regimens.

• OSTI ID: 21587631
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 4 Vol. 80; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
AZINES
BODY
CARBOXYLIC ACIDS
CARCINOMAS
CHEMOTHERAPY
DISEASES
GLOBINS
HEAD
HEMOGLOBIN
HETEROCYCLIC ACIDS
HETEROCYCLIC COMPOUNDS
HYDROXY COMPOUNDS
MATHEMATICS
MEDICINE
METASTASES
MULTIVARIATE ANALYSIS
NAUSEA
NECK
NEOPLASMS
NUCLEAR MEDICINE
ORGANIC ACIDS
ORGANIC COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
ORGANS
PIGMENTS
PORPHYRINS
PROTEINS
PYRIMIDINES
RADIOLOGY
RADIOTHERAPY
SKIN
STATISTICS
SYMPTOMS
THERAPY
TOXICITY
URACILS
VOMITING